Feature | Stents | July 31, 2015

Trio of Drug-Eluting Stents Driving European Interventional Cardiology Market

Abbott Laboratories, Boston Scientific and Medtronic offsetting 10 percent overall decline in 2014

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

July 31, 2015 — According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents accounted for a significant portion of the European markets for interventional cardiology devices in 2014. The advent of drug-eluting stents has driven the interventional cardiology market beyond expectations, as these devices have managed to increase the size of the market by virtue of their relatively high average selling price (ASP). New developments in drug-eluting stents such as biodegradable materials are expected to keep the market competitive despite safety concerns regarding late stent thrombosis.

In 2014, the European markets for interventional cardiology were valued at nearly EUR 1.3 billion, a nearly 10 percent decrease from the previous year. The total European market for interventional cardiology devices is projected to decline as a result of continued decrease in average selling prices due to:

The competitive tender systems being adopted across Europe;
Low procedure numbers; and
A decrease in devices used per procedure due to improvements in medical devices and cardiologist best practices.

 

"Unit sales growth is expected to be driven by a new generation of drug-eluting stents, which are expected to alleviate physician concerns over thrombosis issues, as well as decreased ASPs which may trigger physicians to stent more," explained Kamran Zamanian, Ph.D., CEO of iData.

The negative growth experienced throughout many countries over 2011 and 2012 was due primarily to turbulent macroeconomic conditions throughout the European region. The United Kingdom showed the largest decline due to the entrance of substantially lower priced products being brought into the country from Germany. Benelux and Spain are also expected to see large market declines due to prevalent price erosion and the lackluster unit sales growth in their respective markets. Spending cuts throughout many countries and uncertainty regarding default were major contributors to the stifling of growth of many markets. Austria is expected to be the only country to experience growth due to its premium pricing system modeled after the Swiss market and its proximity to the leading German market.

Abbott Laboratories has been the leading competitor in the drug-eluting stent (DES) market with more than 30 percent market share. Their actual selling price for DES has been quite low due to competition with Boston Scientific. Other competitors include Medtronic, Biotronik, B. Braun, Biosensors International, Cornova and Disa Vascular, among others.

For more information: www.idataresearch.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init